GHRP-6: what the studies show

GHRP-6 and related peptides

GHRP-6 is growth hormone-releasing peptide-6, a synthetic hexapeptide. It is distinct from GHRP-2 and from growth hormone itself. FDA has no approved GHRP-6 human drug product. These peptides' formulations and clinical evidence are not interchangeable.

A hormone-response experiment

A 1990 study gave intravenous GHRP-6 to 18 healthy men and compared acute hormone responses with placebo. Growth hormone rose after administration. At the highest studied exposure, prolactin and cortisol also increased. The study measured short-term physiology. It did not evaluate treatment of a chronic condition.

This intravenous study does not establish a subcutaneous maintenance regimen. Controlled exposure during a laboratory visit cannot supply a validated repeat-use schedule for a different preparation.

Missing clinical outcomes

An increase in circulating growth hormone does not prove added muscle, better physical function, or longer life. Those benefits would require direct trials with relevant outcomes and longer follow-up. FDA's current compounding safety notice flags possible cortisol and blood-glucose effects. Whether any sustained benefit outweighs those risks remains unresolved by the cited experiment.